254 related articles for article (PubMed ID: 28495808)
1. Comprehensive Genomic Profiling of Esthesioneuroblastoma Reveals Additional Treatment Options.
Gay LM; Kim S; Fedorchak K; Kundranda M; Odia Y; Nangia C; Battiste J; Colon-Otero G; Powell S; Russell J; Elvin JA; Vergilio JA; Suh J; Ali SM; Stephens PJ; Miller VA; Ross JS
Oncologist; 2017 Jul; 22(7):834-842. PubMed ID: 28495808
[TBL] [Abstract][Full Text] [Related]
2. Clinically advanced and metastatic pure mucinous carcinoma of the breast: a comprehensive genomic profiling study.
Ross JS; Gay LM; Nozad S; Wang K; Ali SM; Boguniewicz A; Khaira D; Johnson A; Elvin JA; Vergilio JA; Suh J; Miller VA; Stephens PJ
Breast Cancer Res Treat; 2016 Jan; 155(2):405-13. PubMed ID: 26762307
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive Genomic Profiling of Advanced Penile Carcinoma Suggests a High Frequency of Clinically Relevant Genomic Alterations.
Ali SM; Pal SK; Wang K; Palma NA; Sanford E; Bailey M; He J; Elvin JA; Chmielecki J; Squillace R; Dow E; Morosini D; Buell J; Yelensky R; Lipson D; Frampton GM; Howley P; Ross JS; Stephens PJ; Miller VA
Oncologist; 2016 Jan; 21(1):33-9. PubMed ID: 26670666
[TBL] [Abstract][Full Text] [Related]
4. Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common
Elvin JA; Gay LM; Ort R; Shuluk J; Long J; Shelley L; Lee R; Chalmers ZR; Frampton GM; Ali SM; Schrock AB; Miller VA; Stephens PJ; Ross JS; Frank R
Oncologist; 2017 Apr; 22(4):416-421. PubMed ID: 28283584
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations.
Ross JS; Wang K; Khaira D; Ali SM; Fisher HA; Mian B; Nazeer T; Elvin JA; Palma N; Yelensky R; Lipson D; Miller VA; Stephens PJ; Subbiah V; Pal SK
Cancer; 2016 Mar; 122(5):702-11. PubMed ID: 26651075
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations.
Ross JS; Ali SM; Wang K; Khaira D; Palma NA; Chmielecki J; Palmer GA; Morosini D; Elvin JA; Fernandez SV; Miller VA; Stephens PJ; Cristofanilli M
Breast Cancer Res Treat; 2015 Nov; 154(1):155-62. PubMed ID: 26458824
[TBL] [Abstract][Full Text] [Related]
7. Next-Generation Sequencing Reveals Pathway Activations and New Routes to Targeted Therapies in Cutaneous Metastatic Melanoma.
Carlson JA; Caldeira Xavier JC; Tarasen A; Sheehan CE; Otto G; Miller VA; Stephens PJ; Elvin JA; Vergilio JA; Suh J; Gay LM; Ross JS
Am J Dermatopathol; 2017 Jan; 39(1):1-13. PubMed ID: 28045747
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive genomic profiling of malignant phyllodes tumors of the breast.
Nozad S; Sheehan CE; Gay LM; Elvin JA; Vergilio JA; Suh J; Ramkissoon S; Schrock AB; Hirshfield KM; Ali N; Ganesan S; Ali SM; Miller VA; Stephens PJ; Ross JS; Chung JH
Breast Cancer Res Treat; 2017 Apr; 162(3):597-602. PubMed ID: 28210881
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive Genomic Profiling of Advanced Esophageal Squamous Cell Carcinomas and Esophageal Adenocarcinomas Reveals Similarities and Differences.
Wang K; Johnson A; Ali SM; Klempner SJ; Bekaii-Saab T; Vacirca JL; Khaira D; Yelensky R; Chmielecki J; Elvin JA; Lipson D; Miller VA; Stephens PJ; Ross JS
Oncologist; 2015 Oct; 20(10):1132-9. PubMed ID: 26336083
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive Molecular Profiling of Olfactory Neuroblastoma Identifies Potentially Targetable
Lazo de la Vega L; McHugh JB; Cani AK; Kunder K; Walocko FM; Liu CJ; Hovelson DH; Robinson D; Chinnaiyan AM; Tomlins SA; Harms PW
Mol Cancer Res; 2017 Nov; 15(11):1551-1557. PubMed ID: 28775129
[TBL] [Abstract][Full Text] [Related]
11. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
[TBL] [Abstract][Full Text] [Related]
12. Genomic Profiling of Parathyroid Carcinoma Reveals Genomic Alterations Suggesting Benefit from Therapy.
Kang H; Pettinga D; Schubert AD; Ladenson PW; Ball DW; Chung JH; Schrock AB; Madison R; Frampton GM; Stephens PJ; Ross JS; Miller VA; Ali SM
Oncologist; 2019 Jun; 24(6):791-797. PubMed ID: 30373905
[TBL] [Abstract][Full Text] [Related]
13. Targeted 595-gene genomic profiling demonstrates low tumor mutational burden in olfactory neuroblastoma.
Friedman J; Schumacher JK; Papagiannopoulos P; Al-Khudari S; Tajudeen BA; Batra PS
Int Forum Allergy Rhinol; 2021 Jan; 11(1):58-64. PubMed ID: 32558242
[TBL] [Abstract][Full Text] [Related]
14. A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practice.
Vasan N; Yelensky R; Wang K; Moulder S; Dzimitrowicz H; Avritscher R; Wang B; Wu Y; Cronin MT; Palmer G; Symmans WF; Miller VA; Stephens P; Pusztai L
Oncologist; 2014 May; 19(5):453-8. PubMed ID: 24710307
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of 122 advanced-stage cutaneous squamous cell carcinomas by comprehensive genomic profiling opens the door for new routes to targeted therapies.
Al-Rohil RN; Tarasen AJ; Carlson JA; Wang K; Johnson A; Yelensky R; Lipson D; Elvin JA; Vergilio JA; Ali SM; Suh J; Miller VA; Stephens PJ; Ganesan P; Janku F; Karp DD; Subbiah V; Mihm MC; Ross JS
Cancer; 2016 Jan; 122(2):249-57. PubMed ID: 26479420
[TBL] [Abstract][Full Text] [Related]
16. Esthesioneuroblastoma in children, adolescents and young adults.
Dumont B; Lemelle L; Cordero C; Couloigner V; Bernard S; Cardoen L; Brisse HJ; Jehanno N; Fréneaux P; Helfre S; Rouffiange L; Réguerre Y; Orbach D
Bull Cancer; 2020 Sep; 107(9):934-945. PubMed ID: 32896369
[TBL] [Abstract][Full Text] [Related]
17. Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling.
Pal SK; Ali SM; Yakirevich E; Geynisman DM; Karam JA; Elvin JA; Frampton GM; Huang X; Lin DI; Rosenzweig M; Lipson D; Stephens PJ; Ross JS; Miller VA; Agarwal N; Shuch B; Choueiri TK; Chung JH
Eur Urol; 2018 Jan; 73(1):71-78. PubMed ID: 28592388
[TBL] [Abstract][Full Text] [Related]
18. Clinical genomic profiling to identify actionable alterations for very early relapsed triple-negative breast cancer patients in the Chinese population.
Wang L; Zhai Q; Lu Q; Lee K; Zheng Q; Hong R; Wang S
Ann Med; 2021 Dec; 53(1):1358-1369. PubMed ID: 34396843
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive Genomic Profiling of Adult Renal Sarcomas Provides Insight into Disease Biology and Opportunities for Targeted Therapies.
Yakirevich E; Madison R; Fridman E; Mangray S; Carneiro BA; Lu S; Cooke M; Bratslavsky G; Webster J; Ross JS; Ali SM
Eur Urol Oncol; 2021 Apr; 4(2):282-288. PubMed ID: 31412008
[TBL] [Abstract][Full Text] [Related]
20. Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative.
Lim SM; Kim EY; Kim HR; Ali SM; Greenbowe JR; Shim HS; Chang H; Lim S; Paik S; Cho BC
Oncotarget; 2016 Apr; 7(17):24172-8. PubMed ID: 26992220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
